120
Participants
Start Date
November 14, 2024
Primary Completion Date
April 30, 2026
Study Completion Date
August 31, 2026
TQA3605 tablets plus NAs
TQA3605 tablets is core protein regulator
TQA3605 Placebo plus NAs
Placebo without drug substance
NOT_YET_RECRUITING
Beijing Ditan Hospital Capital Medical University, Beijing
NOT_YET_RECRUITING
Beijing Youan Hospital, Capital Medical Universitybeijing Institute of Hepatology, Beijing
NOT_YET_RECRUITING
The sixth people's Hospital Of Shenyang, Shenyang
RECRUITING
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
NOT_YET_RECRUITING
Shanghai Pudong Hospital, Shanghai
NOT_YET_RECRUITING
Shanghai Pudong New District Gongli Hospital, Shanghai
NOT_YET_RECRUITING
Shanghai Tongren Hospital, Shanghai
NOT_YET_RECRUITING
Jiangsu Provincial People's Hospital, Nanjing
NOT_YET_RECRUITING
The Fifth People's Hospital of Suzhou, Suzhou
NOT_YET_RECRUITING
Shandong Public Health Clinical Center, Jinan
NOT_YET_RECRUITING
The First Affiliated Hospital Zhejiang University School Of Medicine, Hangzhou
NOT_YET_RECRUITING
Lishui People's Hospital, Lishui
RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
NOT_YET_RECRUITING
Meng Chao Hepatobiliary Hospital of Fujian Medical University, Fuzhou
NOT_YET_RECRUITING
The Second XIANGYA Hospital Of Central South University, Changsha
NOT_YET_RECRUITING
Yueyang Central Hospital, Yueyang
NOT_YET_RECRUITING
Zhengzhou No.6 peoples Hospital, Zhengzhou
NOT_YET_RECRUITING
Peking University Shenzhen Hospital, Shenzhen
NOT_YET_RECRUITING
Guizhou Provincial People's Hospital, Guiyang
NOT_YET_RECRUITING
Zunyi Medical University Affiliated Hospital, Zunyi
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY